OSLO, NORWAY--(Marketwire - March 19, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its Annual General Meeting 2013:
Algeta's Annual General Meeting will be held on 11 April 2013 at 16:00 hours (CET) at the offices of Algeta ASA at Kjelsåsveien 172A, Oslo, Norway.
Please find attached the Notice of Algeta ASA's Annual General Meeting, proposed amended charter for the nomination committee, and attendance slip and proxy form. These are, together with the annual report, also available on www.algeta.com in the Investor section.
###
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
Notice of Attendance of Annual General Meeting in Algeta ASA: http://hugin.info/134655/R/1686069/552595.pdf
Attendance and proxy form: http://hugin.info/134655/R/1686069/552597.pdf
Proposed amended charter for the Nomination Committee: http://hugin.info/134655/R/1686069/552596.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1686069]
For further information, please contact:
Mike Booth / Renate Birkeli
Communications & Corporate Affairs
+47 23 00 67 32
Email Contact
Media enquiries:
Mark Swallow
Citigate Dewe Rogerson
+44 207 638 9571
Email Contact
Knut Ekern
Gambit Hill & Knowlton
+47 22 04 82 00
Email Contact
Kari Watson
MacDougall Biomedical Communications
+1 781 235 3060
Email Contact
US investor enquiries:
Tricia Swanson
The Trout Group
+1 646 378 2953
Email Contact